Related Experiment Video
Updated: Jun 29, 2025
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
Regression of Intermediate-High Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) With Long-term Use of
Terry Golombick1,2, Rajeev Ramakrishna1,2, Arumugam Manoharan1,2
1Southern Sydney Haematology, Sydney, NSW, Australia.
Abstract:
Patients with intermediate-high risk MGUS are not offered therapeutic options to date and standard of care remains observation with re-evaluations of the patient every 3 to 6 months. Given the persistent risk of progression as well as potential complications experienced by some, and anxiety experienced by most patients, early intervention with non-toxic curcumin, aimed at potentially slowing down or stopping disease progression might be therapeutic. We present here an intermediate-high risk MGUS patient who has been taking curcumin for 16 years and has shown a decrease in disease markers and an increase in uninvolved immunoglobulins, adding to the body of evidence of benefit of curcumin to MGUS patients.
Insights
This study explores curcumin as a potential therapy for monoclonal gammopathy of undetermined significance (MGUS). A long-term MGUS patient taking curcumin showed reduced disease markers, suggesting a potential benefit for managing this condition.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Monoclonal gammopathy of undetermined significance (MGUS) currently lacks therapeutic options, with standard care involving observation every 3-6 months.
- Patients face risks of disease progression, potential complications, and significant anxiety.
- Investigating non-toxic interventions like curcumin is crucial for managing MGUS.
Observation:
- A case study of an intermediate-high risk MGUS patient using curcumin for 16 years.
- The patient was monitored for disease markers and immunoglobulin levels.
Findings:
- The patient demonstrated a decrease in key disease markers.
- An increase in uninvolved immunoglobulins was observed.
- These findings suggest curcumin may positively impact MGUS progression.
Implications:
- Curcumin may offer a therapeutic avenue for slowing or halting MGUS progression.
- This adds to the evidence supporting curcumin's potential benefits in MGUS management.
- Further research into curcumin for MGUS is warranted.
